Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial

In this trial, plant-derived high-dose oral CBD given for 8 weeks as an add-on to continued paracetamol was not superior to continued paracetamol alone for the treatment of pain or impaired function in KOA patients. The primary outcome (change in WOMAC pain subscale over the 8-week study period) did not significantly differ between the placebo and the CBD group. This was also true for all secondary outcome parameters measured.